International Isotopes Inc. (INIS)
| Market Cap | 50.92M |
| Revenue (ttm) | 9.31M |
| Net Income (ttm) | -436,391 |
| Shares Out | 424.05M |
| EPS (ttm) | 0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $0.1200 |
| Previous Close | $0.1300 |
| Change ($) | -0.0100 |
| Change (%) | -7.69% |
| Day's Open | 0.1300 |
| Day's Range | 0.1200 - 0.1303 |
| Day's Volume | 194,421 |
| 52-Week Range | 0.043 - 0.2095 |
News
IDAHO FALLS, Idaho, Jan. 26, 2021 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company") is pleased to announce the following developments. International Isotopes recently s...
IDAHO FALLS, Idaho, Jan. 21, 2021 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company"), due to recent unusual trading volume, and share price volatility in its common stoc...
About INIS
International Isotopes manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services. The company operates in five segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Fluorine Products, and Radiological Services. The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed tomography imaging, patient positioning, and calibration or operational testing... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Aug 14, 1997 |
| CEO Stephen T. Laflin | Employees 35 |
| Stock Exchange OTCMKTS | Ticker Symbol INIS |
Financial Performance
In 2019, INIS's revenue was $8.96 million, a decrease of -13.63% compared to the previous year's $10.37 million. Losses were -$1.52 million, 80.3% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for INIS is 0.12, which is a change of 0.00% from the latest price.